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Context: Steroidogenic factor 1 (SF1/AdBP4/FTZF1, NR5A1) is a
nuclear receptor transcription factor that plays a key role in regu-
lating adrenal and gonadal development, steroidogenesis, and repro-
duction. Targeted deletion of Nr5a1 (Sf1) in the mouse results in
adrenal and gonadal agenesis, XY sex-reversal, and persistent Mu¨l-
lerian structures in males. Consistent with the murine phenotype,
human mutations in SF1 were described initially in two 46,XY indi-
viduals with female external genitalia, Mu¨llerian structures (uterus),
and primary adrenal failure.
Objective: Given recent case reports of haploinsufficiency of SF1
affecting testicular function in humans, we aimed to identify SF1
mutations in a cohort of individuals with a phenotypic spectrum of
46,XY gonadal dysgenesis/impaired androgenization (now termed
46,XY disorders of sex development) with normal adrenal function.
Methods and Patients: The study included mutational analysis of
NR5A1 in 30 individuals with 46,XY disorders of sex development,
followed by functional studies of SF1 activity.
Results: Heterozygous missense mutations in NR5A1 were found in
four individuals (four of 30, 13%) with this phenotype. These muta-
tions (V15M, M78I, G91S, L437Q) were shown to impair transcrip-
tional activation through abnormal DNA binding (V15M, M78I,
G91S), altered subnuclear localization (V15M,M78I), or disruption of
the putative ligand-binding pocket (L437Q). Twomutations appeared
to be de novo or germline changes. The other two mutations appeared
to be inherited in a sex-limited dominant manner because the mother
is heterozygous for the change.
Conclusions: These studies demonstrate that SF1 mutations are
more frequent than previously suspected causes of impaired fetal and
postnatal testicular function in 46,XY individuals. (J Clin Endocri-
nol Metab 92: 991–999, 2007)
STEROIDOGENIC FACTOR 1 [SF1/AD4BP/FTZF1,NR5A1 (MIM 184757)] is a nuclear receptor that plays
a crucial role in the transcription of multiple target genes
involved in adrenal and gonad development, steroidogen-
esis, and reproduction (1, 2). Consistent with these actions,
targeted deletion of Sf1 (Nr5a1) in mice causes complete
adrenal and gonad agenesis, impaired androgenization (vir-
ilization), and retained Mu¨llerian structures in XY animals,
partial hypogonadotropic hypogonadism, and ventromedial
hypothalamic abnormalities (3, 4). Late-onset obesity is re-
ported in adult animals rescued by adrenal transplantation
(5), whereas heterozygous animals have more subtle abnor-
malities in adrenal architecture and stress response, reduced
gonadal size, and impaired testicular somatic cell differen-
tiation (6, 7).
Attempts to identify SF1 mutations in humans initially
focused on the rare group of 46,XY females with primary
adrenal failure, severe gonadal dysgenesis, and Mu¨llerian
structures (uterus, upper vagina): a phenotype similar to the
knockout mice. Two human SF1 mutations that affect DNA
binding have been reported to date in patients with these
features (8, 9). The first patient had a heterozygous de novo
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G35E mutation that disrupts the P-box primary DNA-bind-
ing motif of SF1 and results in decreased target gene binding
and transactivation (8, 10, 11). The second patient had a
homozygous R92Q mutation that disrupts the A-box sec-
ondary DNA-binding motif of SF1, resulting in a variable
and partial loss of SF1 activity (9, 10). Heterozygous carriers
of the R92Q mutation have normal reproductive develop-
ment and adrenal function.
Recently the phenotypic spectrum associated with SF1
mutations in humans has been expanded to include milder
forms of 46,XY gonadal dysgenesis/impaired androgeniza-
tion with normal adrenal function, following case reports of
individuals with heterozygous de novo frameshift or non-
sensemutations inNR5A1/SF1 (8-bpmicrodeletion between
nucleotides 1058–1065; C16X; 18delC) (12–14). These cases
suggest that haploinsufficiency of SF1 can be associated with
a predominantly gonadal phenotype in humans, although it
is possible that these patients could develop an adrenal phe-
notype with time.
Here we report four novel heterozygous missense muta-
tions in NR5A1/SF1 and show that de novo/germline or
sex-limited dominant mutations are a relatively frequent
cause of 46,XY disorders of sex development (DSD) in hu-
mans [previously often referred to as male pseudohermaph-
roditism or intersex and including disorders of gonad (tes-
ticular) development as well and disorders of androgen
synthesis and action] (15). These point mutations are pro-
viding important insight into critical functional domains of this
nuclear receptor and have implications for assessing and coun-
seling individuals and families with reproductive disorders.
Patients and Methods
Patient groups
After institutional review board approval andwith informed consent,
DNA was obtained from 30 patients with 46,XY DSD (SRY positive).
Patients with syndromic forms of gonadal dysgenesis (GD), chromo-
somal abnormalities, and obvious defects in androgen biosynthesis and
action were excluded. The phenotypic spectrum of patients studied
included: 1) complete GD, female external genitalia, uterus (n  12); 2)
partial/mild GD, clitoromegaly, uterus (n  6); 3) partial/mild GD,
female external genitalia, no uterus (n  2); 4) partial/mild GD, cli-
toromegaly/labial rugosity/ambiguous genitalia, no uterus (n 7); and
5) mild GD, hypospadias, no uterus (n 3). No other monogenic causes
of GD were analyzed before NR5A1 (SF1).
Mutational analysis
The entire coding region (exons 2–7) and splice sites of NR5A1 (SF1)
were PCR amplified and sequenced directly using a BigDye Terminator
version 1.1 cycle sequencing kit (Applied Biosystems, Warrington, UK)
and MegaBACE1000 capillary DNA sequencer (Amersham Biosciences,
Buckinghamshire, UK) (9, 16). More than 200 control alleles were
analyzed.
Mutant SF1 expression vectors
For studies of transcriptional activation and dominant negativity,
mutant SF1 expression vectors containing the V15M, M78I, G91S, and
L437Q variants (and previously described G35E and R92Q mutations)
were generated by site-directed mutagenesis (QuikChange; Stratagene,
Amsterdam, The Netherlands) using wild-type (WT) human SF1 cDNA
in a pCMX expression vector as a template. WT and mutant GFP-SF1
constructs were generated by cloning WT SF1 cDNA in-frame into a
pAcGFP-C1 vector (CLONTECH, Oxford, UK) to produce a fusion pro-
tein of SF1 with a monomeric green fluorescent protein (GFP) tag at its
amino-terminal end. Mutant pAcGFP-C1-SF1 vectors (V15M, G35E,
M78I, G91S, R92Q, and L437Q) were generated by site-directed mu-
tagenesis, using the WT construct as a template (QuikChange; Strat-
agene). The entire sequence of allmutant plasmidswas confirmed before
functional studies.
Studies of transcriptional activation
Transient gene expression assays were performed in 96-well plates
(Techno Plastic Products, Trasadingen, Switzerland) using tsa201 hu-
man embryonic kidney cells or Chinese hamster ovary (CHO) cells,
lipofectamine 2000 (Invitrogen, Paisley, UK), and a dual-luciferase re-
porter assay system (Promega, Southampton, UK)with cotransfection of
pRLSV40 Renilla luciferase (Promega) as a marker of transfection effi-
ciency. For analysis of target gene transcriptional activation, pCMXWT
or mutant SF1 expression vectors (2 ng/well) were cotransfected into
tsa201 cells with reporters containing SF1-responsive minimal promot-
ers (murine Cyp11a, rat Cyp19, murine Insl3/relaxin-like factor, and
human MIS) (100 ng/well), as reported previously (10, 17). Synergistic
activation of the rat LH promoter was studied using 2 ng pCMXWT or
mutant SF togetherwith 2 ng/well of pCMXEgr1 (early growth response
1) (18). In all studies, cells were lysed 24 h after transfection and lucif-
erase assays performed (dual luciferase reporter assay system; Promega)
using a FLUOstar Optima fluorescence microplate reader (BMG
Labtech, Aylesbury, UK). All data were standardized for Renilla coex-
pression. Results are shown as the mean  sem of at least three inde-
pendent experiments, each performed in triplicate.
Studies of WT/mutant interactions
Studies of WT/mutant interactions were performed using a 1:1 ng
mix of WT-mutant vector on each promoter in tsa201 cells, as well as by
transfecting WT or mutant SF (2 ng) into a CHO cell line with low-level
endogenous Sf1 expression and assessing transactivation of the Cyp11a
reporter (100 ng). In addition, increasing amounts of pCMXWT or mu-
tant SF1 expression vector (0, 1, 2, 5, 10 ng)were cotransfectedwith either
1 ng empty vector or 1 ng WT SF1 cDNA and Cyp11a reporter (100 ng)
in tsa201 cells to assess for potential dominant-negative effects when
increasing ratios of mutant to WT vectors (up to 10:1) were used.
Alternative cell lines
In addition to using the SF1 neutral cell line (tsa201) described above,
transient transfection studies of WT and mutant SF1 activity were per-
formed in NCI-H295R human adrenal carcinoma cells, TM3 mouse
Leydig cells, and TM4mouse Sertoli cells, using 150 ng/well of reporter
(Cyp11a,Cyp11a,MIS) and 5, 20, and 10 ng/well of SF1 expression vector,
respectively.
Studies of SF1 expression, nuclear localization, and
nucleolar immunofluorescence
WT and mutant pAcGFP-C1SF1 expression vectors (0.8 g) were
transfected into tsa cells using lipofectamine 2000 (Invitrogen). After
24 h, cells were fixed and nuclear counterstaining performed with
Vectashield-containing 4,6-diamidino-2-phenylindole (Vector Labora-
tories, Peterborough, UK). Cells were visualized using an Axioskop
microscope and camera (Zeiss, Oberkochen, Germany). Nucleolar im-
munofluorescence was performed using a primary monoclonal -C23
antinucleolin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at
1:100 dilution, and a secondary rhodamine tetramethylrhodamine iso-
thiocyanate porcine antirabbit antibody (DakoCytomation, Glostrup,
Denmark) at a dilution of 1:30.
DNA binding
In vitro translation of WT and mutant SF1 proteins was performed
using the TNT reticulocyte system (Promega). Synthetic oligonucleo-
tides corresponding to the SF1 response elements of target genes were
generated; data for the 3 SF1 binding site on the Cyp11a minimal pro-
moter are shown (5-GCTTCTCTCTTAGCCTTGAGCTGGTT-3, SF1
site underlined). Probes were labeled with [32P]dCTP by Klenow poly-
merase, and EMSAs were performed as described previously (10). Bind-
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ing to in vitro-translated empty vector (lane 1) and a 100 excess of cold
probe together with WT protein (lane 9) were used as controls.
Results
Case histories
Patient 1 (V15M). Patient 1 was born to British Caucasian
parents. Chorionic villus sampling revealed a 46,XY karyo-
type, but the baby was born with female external genitalia,
and bilateral gonads (testes) were palpable in rugose labia.
Endocrine investigations were consistent with gonadal dys-
genesis with impaired androgen biosynthesis (Table 1). The
46,XY karyotype was confirmed and adrenal function was
normal. The baby was raised female and gonadectomy was
performed at 4 months of age. Histology revealed small
gonads (8 mm)with well-formed testicular tissue with abun-
dant seminiferous tubules (Fig. 1A), multiple germ cells (Fig.
1B), andwell-developed vasa deferentia and epididymes.No
Mu¨llerian structures were present and there was a small
blind-ending vagina with closed internal inguinal rings. Mu-
tational analysis revealed a heterozygous de novo (or germ-
line) valine to methionine (V15M) mutation, which affects a
highly conserved amino acid in the first zinc finger of the
DNA-binding domain (DBD) of SF1 (Fig. 2, A–C). Parents are
wild type for this sequence.
Patient 2 (M78I).Patient 2 is the first child of ItalianCaucasian
parents. Amniocentesis had revealed a 46,XY karyotype, but
normal female external genitalia were apparent at birth with
bilateral gonads (testes) palpable on deep inguinal palpation.
Endocrine investigations at 5 months of age showed poor
testosterone response to human chorionic gonadotropin
(hCG) stimulation, very low Mu¨llerian inhibiting substance
[MIS/anti-Mu¨llerian hormone (AMH)], and normal adrenal
steroids (Table 1). Gonadectomy at 7 months of age revealed
small testeswith seminiferous tubules, scarce germ cells (Fig.
1C), and well-developed vasa deferentia and epididymes.
Interstitial cells appeared vacuolated (Fig. 1D) and a Mu¨l-
lerian duct remnant was present. Mutational analysis iden-
tified a heterozygous methionine to isoleucine (M78I) mu-
tation, which affects a highly conserved region of SF1
between the DNA-binding zinc fingers and A-box region
(Fig. 2, A–C). The mother carried this M78I change.
TABLE 1. Genetic, clinical, and biochemical features of patients with SF1 mutations reported here
Patient Normal values
(mean  SD or range)1 2 3 4
Mutation V15M M78I G91S L437Q
Inheritance Heterozygous; de novo or
germline
Heterozygous; sex-
limited dominant
Heterozygous; sex-
limited dominant
Heterozygous;
de novo or germline
Karyotype 46,XY 46,XY 46,XY 46,XY
Phenotype Female Female Clitoral enlargement Small phallus
Labial rugosity Labioscrotal folds Penoscrotal hypospadias
Gonad position Labial Inguinal Labioscrotal High scrotal
Gonad histology Testis Testis Testis Hyalinized testisa
Germ cells Germ cells Germ cells Few germ cells
Müllerian structures Absent Remnant Remnant Absent
Additional features Partial HH
LH (IU/liter)
Basal 2.3 0.5b 2.1 21.4 2.3 2.2; 0.8b
Peak 10 28b 13 NA 0.5–6.9b
FSH (IU/liter)
Basal 9.5 21b 1.9; 8.2 7.4 2.9 4.3; 0.4–3.0b
Peak 24 81b 16 NA 2.0–4.0b
Testosterone (ng/dl)
Basal 3 16b 23 20 30–90; 5.0–50b
Peak 9c 62b,d 43e 20e; 226c,f 150le; 365c
MIS (ng/ml) 7.3 3.2b NA NA 15–48; 29–57b
ACTH (pg/ml) 19 105g; 29h 22 NA 10–70
Cortisol (g/dl)
Basal 12 6.2g; 10.1h 11 15 3.0–15
Peak 35 26.3h 23 31 18
Aldosterone (ng/dl) 93 NA 69 99 36–162
Plasma renin activity
(ng/mlh)
8.5 15g 15 22 32; 7.0–20g
All basal values were obtained between 7 and 10 d of life, unless indicated. Conversion to SI units: testosterone, nanograms per deciliter 
0.0347 for nanomoles per liter; AMH, nanograms permilliliter 7.14 for picomoles per liter; ACTH, picograms permilliliter 0.22 for picomoles
per liter; cortisol, micrograms per deciliter  27.6 for nanomoles per liter; plasma renin activity, nanograms per milliliter per hour  0.77 for
picomoles per milliliter per hour; aldosterone, nanograms per deciliter  27.7 for picomoles per liter. NA, Not available.
a Histology obtained at 6 yr of age.
b Data at 5 months of age.
c Three-week hCG stimulation test.
d One-week hCG stimulation.
e Three-day hCG stimulation.
f Data at 9 months of age.
g Data at 40 d of age.
h Data at 10 yr of age.
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Patient 3 (G91S). Patient 3 was the first child born to Fijian
parents and was noted to have clitoral enlargement (1 cm)
with a single perineal opening. Gonads (testes) were palpa-
ble in the labioscrotal folds. Karyotype was 46,XY. The child
was raised female and gonadectomy was performed at 4
months of age. Histology revealed testes (10 mm) containing
abundant seminiferous tubules with Sertoli cells and multi-
ple germ cells (Fig. 1, E–F), although tubule density was
reduced in some areas. The vasa deferentia and epididymes
appeared normal and Mu¨llerian structures were absent, al-
though a Mu¨llerian duct remnant with ciliated epithelium
was identified close to the testis (Fig. 1G). Endocrine inves-
tigations were consistent with gonadal dysgenesis/impaired
androgen biosynthesis (Table 1). Adrenal investigations
were normal. Mutational analysis revealed a heterozygous
glycine to serine (G91S) mutation in the A-box region of SF1
(Fig. 2, A–C). The same heterozygous G91S change was
present in the mother.
Patient 4 (L437Q). Patient 4 was the only child born to British
Caucasian parents and was noted at birth to have a small
phallus with severe penoscrotal hypospadias and chordee
but moderate corporal tissue. Bilateral testes were palpable
and could be brought down into the scrotum. Karyotypewas
46,XY and endocrine investigations were consistent predom-
inantly with impaired androgen biosynthesis (Table 1). Ad-
renal functionwas normal. He respondedwell to three cycles
of testosterone treatment (25 mg) in early infancy and had a
hypospadias repair at 14 months of age. At 6 yr of age, he
required bilateral orchidopexies to secure the testes in the
scrotum.Abiopsy of the right testis taken at this time showed
separated hyalinized noncannulated seminiferous tubules
with a predominantly Sertoli cell-only pattern and very few
scattered germ cells (Fig. 1H). Leydig cells were not identi-
fied, as is typical for this age. Mutational analysis revealed
a heterozygous de novo (or germline) leucine to glutamine
mutation (L437Q) affecting a highly conserved amino acid in
the ligand-binding domain (LBD) of SF1 that is predicted
from the crystal structure of SF1 to form part of the phos-
pholipid ligand binding pocket (Fig. 2A) (19–21). Parents are
wild type for this sequence.
Further investigation of the hypothalamo-pituitary-go-
nadal endocrine axis in late childhood and adolescence in
this patient suggested a partial form of hypogonadotropic
hypogonadism in additional to a primary testicular defect. At
8 yr of age, his testosterone response to 3-d stimulation with
hCG was flat [basal testosterone, 23 ng/dl (0.8 nmol/liter);
peak testosterone, 17 ng/dl (0.6 nmol/liter); normal re-
sponse 150 ng/dl (5nmol/liter); our unpublished data and
others], and he had an absent LH response to bolus LHRH
stimulation (LHbasal, 0.5 IU/liter; LHpeak, 0.5 IU/liter;
FSH basal, 0.2 IU/liter; FSH peak, 4.3 IU/liter). Prolonged
hCG stimulation for 3 wk at 12 yr of age produced a peak
testosterone of 226 ng/dl [7.0 nmol/liter; normal response
365 ng/dl (12.6 nmol/liter); our unpublished data]. He
showed only limited spontaneous progress in puberty by
13.3 yr [pubertal ratings: Tanner G2, P1, A1, 4–5 cc testicular
volumes; LH, 1.7 IU/liter; FSH, 11.0 IU/liter; testosterone, 64
ng/dl (2.2 nmol/liter); normal gonadotropin values: LH
basal,  0.5–2.7 IU/liter; FSH basal,  1.0–4.4 IU/liter; val-
ues normally considerably higherwhen testicular dysgenesis
is present] and was started on supplemental testosterone
therapy to induce puberty.
FIG. 1. Photomicrographs demonstrating representative gonadal
histology frompatients 1–4 (hematoxylin and eosin). A andB, Patient
1 (V15M) had small gonads removed at 4 months of age, demonstrat-
ing relatively preserved testicular architecturewithwell-formed sem-
iniferous tubules (A, original magnification, 100) and numerous
germ cells (arrowhead, B, original magnification, 400). C and D,
Patient 2 (M78I) had gonadectomy performed at 7months of age. Less
dense seminiferous tubules were detected (C, original magnification,
200), with scattered germ cells and vacuolated interstitial cells
(arrowhead, D, original magnification, 400). E–G, Patient 3 (G91S)
also had gonads removed at 4 months of age in which the overall
testicular architecture was intact, although seminiferous tubule den-
sity was reduced in some areas (E, original magnification, 100).
Germ cells were readily identified in most seminiferous tubules (ar-
rowheads, F, original magnification,400). Small bilateral utricular-
like structures were identified in close proximity to the testes bilat-
erally, with loose stroma and focally ciliated columnar epithelium
(arrowheads indicate cilia, G, original magnification, 400). H, Pa-
tient 4 (L437Q) had a testicular biopsy performed during orchidopexy
at 6 yr of age, demonstrating separated hyalinized seminiferous tu-
bules with a predominant Sertoli cell only phenotype (original mag-
nification, 100).
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Functional studies of SF1 activity
Using embryonic kidney tsa201 cells, analysis of WT and
mutant SF1 function in transient gene expression assays
showed markedly impaired activity for all mutants on a
range of different native SF1 target gene promoters (Cyp11a,
Cyp19, Insl3, MIS), as well as in synergistic activation of the
LH promoter with Egr1 (Fig. 3, A–F). In comparison, the
R92Q A-box mutant previously described in a homozygous
state in a patient with severely impaired androgenization
and adrenal failure had partial activity.
Studies of WT/mutant interactions
Cotransfection of mutant with WT SF1 did not show a
strong dominant-negative effect when transfected in a 1:1
ratiowithWTvector in tsa201 cells (Fig. 4, A and B) or a CHO
cell line with endogenous SF1 expression (Fig. 4C) or when
increasing amounts of mutant vector were used against a
fixedWT vector concentration (Fig. 4D). The G35E and G91S
mutants showed a small reduction in WT activity when
greater quantities of plasmid were cotransfected, but, even
with a 10:1 mutant to WT ratio, WT activity was not reduced
FIG. 2. Overview of SF1 mutations in 46,XY patients with DSD. A, Cartoon of the structure of SF1 showing key functional domains and the
position ofmissensemutants described in 46,XY individualswith gonadal dysgenesis/impaired androgenization, with (G35E, R92Q) andwithout
(V15M, M78I, G91S, L437Q) adrenal insufficiency. B, Structure of the SF1 zinc-finger DBD and position of mutations V15M, G35E, and M78I.
C, Homology of the DBDs of SF1 between species, with the zinc-finger DNA-binding region shown as the first shaded area (left) and the A-box
DNA-binding region as the second shaded area (right). Humanmissense mutations are indicated by asterisks and affect highly conserved amino
acids.
FIG. 3. Transcriptional activation of SF1 target gene promoters by WT and mutant SF1. Data for the missense mutations reported here in
patients with 46,XY DSD but normal adrenal function (V15M, M78I, G91S, L437Q) are shown together with data for those missense mutations
found in patients with adrenal failure (G35E, R92Q). All mutations were identified in the heterozygous state, other than the R92Q partial
loss-of-function mutation that produced a phenotype in the homozygous state. A–D, Data for the Cyp11a, Cyp19, Insl3, and MIS minimal
promoters expressed as percentage of WT activity. E, Data for synergistic activation of the LH promoter with SF1 (WT or mutant) and Egr1.
A robust response with the R92Q partial mutant is typically seen. F, Mean transcriptional activation of WT and mutant SF1 for all five studies
(A–E). In studies A–E, data represent themean SEM of three independent experiments, each performed in triplicate. RLU, Relative light units.
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less than 50% and never completely extinguished. Thus, al-
though a competitive or mild dominant-negative effect may
be present with these mutant proteins, a classic dominant-
negative effect is not observed.
Alternative cell lines
The V15M, M78I, and G91S mutants showed loss of func-
tion in adrenal, Leydig, and Sertoli cell lines, whereas the
L437Q ligand-binding domain mutant retained partial ac-
tivity in these cell systems, consistent with themilder clinical
phenotype of this patient (hypospadias, male gender assign-
ment) (Fig. 4, E–G).
SF1 expression and cellular localization
GFP-tagged WT SF1 showed strong nuclear localization
with nucleolar exclusion (Fig. 5, A–C). A similar pattern of
nuclear localization was seen for most mutant SF1 species
(G35E, G91S, R92Q, L437Q) (Fig. 5B). In addition, the V15M
and in particular M78I constructs showed strong subnuclear
foci in many of the transfected cells (Fig. 5B). These foci were
shown to be extranucleolar (Fig. 5C).
Studies of DNA binding to target genes
EMSAs showed significantly impaired binding by the
V15M, G35E, M78I, and G91S mutants, whereas the R92Q
mutant had partial loss of binding to a native SF1 target
sequence (Cyp11a, 3 SF1 site) (Fig. 5D). As expected, binding
was not impaired for the L437Q LBD mutant.
Discussion
The diagnosis and management of the 46,XY infant with
severe underandrogenization or genital ambiguity is one of
FIG. 4. Studies ofWT/mutant interaction to investigate a potential dominant-negative effect and studies of SF1 activity in alternative cell lines.
A and B, Cotransfection of 1 ng WT SF1 with 1 ng empty (), WT, or mutant SF1 expression vector and a Cyp11a (A) or MIS (B) promoter
reporter (100 ng) in tsa201 cells. C, Cotransfection of 2 ng empty (), WT, or mutant SF1 expression vector with a Cyp11a promoter reporter
(100 ng) in CHO cells, a cell line with low levels of endogenous SF1 expression. D, Transfection of increasing amounts of empty (), WT, or
mutant SF1 expression vector (0, 1, 2, 5, 10 ng) with 1 ng empty vector () or 1 ng WT and a Cyp11a promoter reporter (100 ng) in tsa201 cells.
Additional empty vector was transfected to keep DNA quantities consistent. E–G, Transient transfection studies ofWT andmutant SF1 activity
in SF1-expressing cell lines (NCI-H295R, human adrenal carcinoma cells; TM3, mouse Leydig cells; TM4, mouse Sertoli cells) using appropriate
reporters (Cyp11a,Cyp11a,MIS) (150ng) and 5, 20, and 10ng/well of SF1 expression vector, respectively.Data shown (A–C,E–G) are themean
SEM of three independent experiments, each performed in triplicate. Data in D are typical data from a single experiment, performed in triplicate.
RLU, Relative light units.
996 J Clin Endocrinol Metab, March 2007, 92(3):991–999 Lin et al. • SF1 and 46,XY Sex Development
the greatest challenges faced by pediatric endocrinologists,
urologists, and geneticists. Making a correct diagnosis can
have implications for gender assignment, the likely response
to hormone treatment, sexual function, fertility options, go-
nadal malignancy risk, and provision of informed and ap-
propriate counseling to the family. Thus, improving our un-
derstanding of the genetic basis of DSD in humans has
important translational consequences (15).
SF1 is a nuclear receptor that plays a central role in adrenal
and reproductive function because it influences gene transcrip-
tion at multiple levels and at different stages of development.
Complete loss of Sf1 function inmice results in apoptosis of the
developing adrenal gland and gonad during early embryogen-
esis (3, 4). The first human SF1 mutation, a heterozygous G35E
change, was reported in a 46,XY female patient with primary
adrenal failure, relatively severe gonadal dysgenesis, andMu¨l-
lerian structures (8). Subsequently the description of a homozy-
gous R92Q mutation in SF1 in an infant with a similar pheno-
type led to the proposal that functional gene dosage effects of
SF1 are important and that loss of SF1 function between hap-
loinsufficiency and null can be associated with a gonadal and
adrenal phenotype in humans (9, 22).
Recent reports of three heterozygous frameshift or nonsense
mutations in NR5A1/SF1 (1058–1065del8bp, 18delC, C16X) in
patients with 46,XY DSD and apparently normal adrenal func-
tion support the concept that haploinsufficiency of SF1 (or par-
tial loss of function) can present with a predominantly gonadal
phenotype in humans (12–14). In this current report, we show
that heterozygous missense mutations in critical regions of
NR5A1/SF1 can be associated with 46,XY DSD and normal
adrenal function and that suchNR5A1/SF1 mutations account
for 13% of cases of previously undiagnosed 46,XY gonadal
dysgenesis/impaired androgenization.
The SF1 mutations identified in our cohort were found
predominantly in individuals with impaired Leydig cell
function and androgen biosynthesis rather than significant
gonadal dysgenesis or classic Swyer syndrome (complete
gonadal dysgenesis and Mu¨llerian structures). Testicular ar-
chitecture was relatively intact postnatally in the three in-
dividuals with amino-terminal mutations (V15M, M78I,
C91S) who were raised female and underwent early gonad-
ectomy. Mu¨llerian regression had occurred in all cases, and
the androgen response to hCG stimulation was surprisingly
impaired for testicular size and location. Although AMH
levels were low in the two cases studied, this finding may
reflect impaired SF1 transcription of the AMH promoter
rather than a direct consequence of Sertoli cell dysfunction.
Well-developed Wolffian structures (vasa deferentia, epi-
didymes) were present, which are an unusual feature in
46,XY patients with such significant underandrogenization.
FIG. 5. Studies of SF1 expression, cellular localization, andDNAbinding. GFP-SF1 fusion proteins (green) were created and expressed in tsa201
cells using a pAcGFP-C1 vector. Nuclear counterstaining was performed with 4,6-diamidino-2-phenylindole (DAPI) (blue) and images merged
to confirm nuclear localization. A, Empty vector () showed diffused localization throughout the cell cytoplasm and nucleus (upper panels). WT
SF1 showed strong nuclear localization, with relative nucleolar exclusion and very occasional nuclear subfoci (lower panels). B, A similar
expression and localization pattern to WT was seen for the G35E, G91S, R92Q, and L437Q mutants. The V15M mutant showed nuclear
localization with fine subnuclear foci. Clustering in larger subnuclear foci was seen in many cells transfected with the M78I SF1 mutant. C,
Immunofluorescence with an antinucleolin antibody (-c23) (red) confirmed nucleolar exclusion of theWTSF1 protein (upper panel) and showed
that the subnuclear foci seen with the V15M and M78I mutants were extranucleolar (middle and lower panels). D, Studies of DNA binding.
EMSA of binding of in vitro-translated WT or mutant SF1 proteins to a labeled probe corresponding to the 3 SF1 binding site of the Cyp11a
promoter. In vitro-translated empty vector () (lane 1) and an excess of unlabeled probe (with WT SF1 protein) (lane 9) were used as controls.
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The identification of naturally occurring missense muta-
tions in SF1 is also helping to reveal important functional
domains for nuclear receptor action. The threemutations that
lie within the very highly conserved amino-terminal region
of the protein (V15M, M78I, G91S) affect DNA binding and
target gene transactivation (Figs. 2, A and C, 3, and 5). The
valine to methionine mutation at codon 15 (V15M) is a rel-
atively mild disruption but lies in a critical part of the first
zinc-finger of the DBD (Fig. 2, B and C) (10). The glycine to
serine mutation at position 91 (G91S) affects a crucial amino
acid in the A-box region of the FTZ-F1 domain, which is
involved in stabilizing DNA binding by monomeric recep-
tors through an interactionwith the PyCA-flanking sequenc-
ing of the half-site (PyCA AGGPyCPu) in the minor groove
of DNA. A partial loss-of-function mutation in an adjacent
codon (R92Q) was reported previously, with phenotypic ex-
pression only in the homozygous state (9, 10). The methio-
nine to isoleucine mutation at position 78 (M78I) affects a
highly conserved codon between the zinc fingers and A-box
in the amino-terminal region of the FTZ-F1 domain (Fig. 2C)
(23). Although relatively little is known about this region, our
studies of GFP-SF1 fusion proteins show that this M78I mu-
tation exhibits marked clustering in subnuclear promyelo-
cytic leukemia (or ND10) bodies in many cells (Fig. 5. B and
C) as well as impaired DNA binding (Fig. 5D).
Similar aggregation has been reported for mutations in
several other nuclear receptors (e.g. estrogen receptor, an-
drogen receptor, glucocorticoid receptors) or after stimula-
tion with signaling pathway activators or when associated
with cofactor (e.g. GRIP1, RIP140) as part of a ubiquitin-
proteosome complex or within the preassembly transcrip-
tional complex machinery (24–28). Recent data have also
demonstrated focal clustering for SF1 after protein kinase A
pathway stimulation (29), when associated with coactivators
and corepressors (e.g. GCN5, DAX1) (30), and after recruit-
ment of SF1 by p300/cAMP response element-binding pro-
tein (CREB)-binding protein (CBP) to a p300-RNA Pol II
locus before acetylation, DNA binding, and transcriptional
activation (31). Thus, it is possible that the M78I mutant (and
V15M) becomes aggregated in these complexes and prevents
subsequent transcriptional activation or cannot dissociate
from the complexes causing sequestration of cofactors and
transcriptional machinery. Such mechanisms may be an im-
portant additional means by which mutations in nuclear re-
ceptor transcription factors can cause human disease. Finally,
disparate effects between the G35E and other point mutants
were not seen in the different cell lines studied here. Thus, the
G35E mutant may have partial dominant-negative effects in
morecomplexoradrenal-specificgene transcriptionsystems,or
modifier loci may be important in dictating the predominantly
gonadal vs. combined gonadal and adrenal phenotype.
In contrast to these DNA-binding region mutations, the
L437Q mutation is the first ligand-binding region mutation
reported in SF1 and is the first reported case of a mild phe-
notype (penoscrotal hypospadias) in a patient raised male.
Consistent with this phenotype, the L437Q SF1 mutant re-
tained partial function in several SF1-expressing cell lines
(Fig. 4, E–G). In contrast, his testicular biopsy at 6 yr of age
showed more marked changes than in subjects 1–3. Whether
these histological changes represent a progressive postnatal
deterioration in testicular integrity with time or the conse-
quences of testicular maldescent is unclear. Analysis of fur-
ther patients with SF1 mutations who are raised male will be
necessary to confirm whether progressive testicular changes
occur with time.
Recently the putative LBD of SF1 has been crystalized and
shown to interact with phospholipid ligands (19–21). These
ligands may be important in the interface between phospha-
tidylinositol 3-kinase signaling pathways and SF1 activation.
The L437Q mutation reported here affects an amino acid
thought to interact directly with the phospholipid ligand as
part of the ligand-binding pocket. The leucine to glutamine
mutation would be predicted to destabilize this domain
through replacement of the hydrophobic side chain with the
polar amide group (19–21). Of note, this patient appears to
be developing a partial form of hypogonadotropic hypogo-
nadism in addition to a primary testicular defect. Phospha-
tidylinositol 3-kinase-dependent signaling may be more im-
portant in the gonadotrope, compared with the adrenal (32,
33). Further studies through adolescence will be necessary to
validate this hypothesis, once puberty has been inducedwith
sex steroid supplementation.
Taken together, these cases show that heterozygous mis-
sense mutations in NR5A1/SF1 are emerging as a relatively
frequent association with 46,XY disorders of sex develop-
ment with intact adrenal steroid biosynthesis. Whether these
patients will develop adrenal failure with time remains to be
seen, but this study supports the hypothesis that, in humans,
the developing testis may be more sensitive to disruption by
partial loss of SF1 function than the developing adrenal gland
(22, 34) and that androgen biosynthesis is more severely
affected than testicular integrity. Furthermore, the apparent
sex-limited dominant transmission ofNR5A1/SF1mutations
in two cases here (M78I, G91S) support reports of preserved
ovarian development and function in a 46,XX girl who has
adrenal failure due to a heterozygous R255Lmutation in SF1
(35). Indeed, ovarian development is relatively preserved
after tissue-specific targeted deletion of Sf1 in mice, possibly
due to the compensatory role of the related nuclear receptor
LRH1 (NR5A2) (36, 37). The families described here could be
at risk of having future affected 46,XY fetuses or carrier
daughters, similar to an X-linked pattern of inheritance. Fur-
ther studies will be necessary to establish the exact preva-
lence ofNR5A1/SF1mutations in patients with reproductive
disorders, the long-term risk of adrenal dysfunction,whether
different disease mechanisms (e.g. ligand-binding defects,
nuclear aggregation) have different clinical consequences,
and whether polymorphic variants of SF1 (e.g. G146A) are
important modifiers of phenotypic expression of reproduc-
tive disorders (38, 39).
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